DIABETIC DYSLIPIDEMIA - TREATMENT IMPLICATIONS

被引:0
|
作者
BETTERIDGE, DJ
机构
关键词
CARDIOVASCULAR DISEASE; DIABETES; DIABETES TREATMENT; DYSLIPIDEMIA; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetes is associated with increased morbidity and mortality from cardiovascular disease in the absence of the major risk factors-cigarette smoking, hypertension and serum cholesterol concentration. When these risk factors are present, the attributable risk to each factor alone and to the combination of risk factors is higher in diabetic than in nondiabetic subjects. Thus, stringent measures to correct risk factors for cardiovascular disease have been advocated in diabetic patients. In addition to hypercholesterolaemia, other lipid and lipoprotein abnormalities collectively referred to as diabetic dyslipidaemia probably contribute to vascular risk. Hypertriglyceridaemia, often associated with low high-density-lipoprotein cholesterol, is common in NIDDM patients and is associated with insulin resistance. Recent information in diabetic patients, pointing to the association of hypertriglyceridaemia with accumulation of remnant particles and alterations in low-density-lipoprotein subfractions, helps to explain the strong relationship between hypertriglyceridaemia and vascular risk in these individuals. Although there are as yet no intervention trials with lipid-lowering diets or drugs in diabetic patients to judge the impact on vascular disease, national and international bodies have furnished guidelines for the identification and treatment of lipid disorders in diabetes in the hope of reducing the huge toll of vascular disease in these patients.
引用
收藏
页码:47 / 52
页数:6
相关论文
共 50 条
  • [21] Diabetic dyslipidemia
    Wu, Liya
    Parhofer, Klaus G.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2014, 63 (12): : 1469 - 1479
  • [22] Diabetic dyslipidemia
    Chahil, Tina J.
    Ginsberg, Henry N.
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2006, 35 (03) : 491 - +
  • [23] Diabetic dyslipidemia
    Kreisberg, RA
    AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (12A): : 67U - 73U
  • [24] TREATMENT OF DYSLIPIDEMIA IN DIABETIC TYPE 2 PATIENTS WITH HYPERTENSION
    Maglapheridze, Zviadi
    Tabukashvili, Revaz
    Kapetivadze, Vera
    Tchaava, Khatuna
    Gegeshidze, Nino
    Lazashvili, Tamar
    Grigorashvili, Zurab
    ATHEROSCLEROSIS, 2017, 263 : E217 - E217
  • [25] Diabetic Dyslipidemia: Epidemiology and Prevention of Cardiovascular Disease and Implications of Newer Therapies
    Haider J. Warraich
    Jamal S. Rana
    Current Cardiology Reports, 2018, 20
  • [26] Diabetic Dyslipidemia: Epidemiology and Prevention of Cardiovascular Disease and Implications of Newer Therapies
    Warraich, Haider J.
    Rana, Jamal S.
    CURRENT CARDIOLOGY REPORTS, 2018, 20 (12)
  • [27] Should the treatment of diabetic dyslipidemia be changed after the ACCORD study?
    Pedro-Botet, J.
    Millan, J.
    Pinto, X.
    AVANCES EN DIABETOLOGIA, 2010, 26 (04): : 220 - 221
  • [28] Diabetic dyslipidemia and response to intensified glycemic treatment: Why there are differences?
    Baroni, MG
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2005, 28 (10) : 869 - 870
  • [29] Review: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia
    Ginsberg, HN
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (02): : 383 - 392
  • [30] Insights into incretin-based therapies for treatment of diabetic dyslipidemia
    Stemmer, Kerstin
    Finan, Brian
    DiMarchi, Richard D.
    Tschoep, Matthias H.
    Mueller, Timo D.
    ADVANCED DRUG DELIVERY REVIEWS, 2020, 159 : 34 - 53